Brought to you by:
New analysis details learning curve effect behind ‘significant improvement’ in performance of PE mechanical thrombectomy over time
A multisite hospital system analysis of the safety and procedural learning curve behind the performance of percutaneous mechanical thrombectomy for pulmonary embolism (PE) shows significant reductions in both fluoroscopy and procedure times alongside contrast volume over time. The data, the…
Akura Medical enrols first patient in QUADRA-PE study
Akura Medical has announced today the first patient enrolment in the QUADRA-PE study evaluating the Katana thrombectomy system in patients with acute pulmonary embolism (PE). The initial procedure was successfully performed by Samuel Horr, director of cardiovascular research at TriStar Centennial…
New analysis shows patients treated with Penumbra’s CAVT technology for PE utilize fewer hospital resources
Penumbra has announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra’s computer-assisted vacuum thrombectomy (CAVT) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other…
TCT 2024: PEERLESS trial finds large-bore mechanical thrombectomy superior for intermediate-risk PE
Findings from the first international randomised controlled trial (RCT) to compare patient outcomes following treatment with large-bore mechanical thrombectomy (LBMT) versus catheter-directed thrombolysis (CDT) for intermediate-risk pulmonary embolism (PE) found that LBMT is superior with respect to the hierarchically-tested aggregated…
Thrombolex begins enrolment in RAPID-PE study of Bashir catheter
Thrombolex has announced the enrolment of the first two patients in the RAPID-PE study using the Bashir endovascular catheter for the treatment of acute pulmonary embolism (PE). The patients were enrolled by Ayman Iskander (St Joseph’s Health Hospital, Syracuse, USA).…
Inari Medical updates ClotTriever XL IFU amid FDA recall notice
The Food and Drug Administration (FDA) has issued a Class I recall—the most serious type—for Inari Medical‘s ClotTriever XL, 30mm device due to reports of patient injury, and death from device entrapment and pulmonary emboli (PE). The device remains on…
Thrombolex and Aidoc announce strategic partnership to advance breakthrough PE treatment
Thrombolex and Aidoc have announced a strategic partnership aimed at revolutionising the treatment of acute pulmonary embolism (PE), a press release reports. This strategic collaboration, the release details, will leverage Aidoc’s artificial intelligence (AI) technology to accelerate patient identification and…
Unmet needs and paradigm shifts: VESS scientific sessions set to plumb the vasculature for advances in practice
Selected research to be presented during the Wednesday afternoon, June 19, series of Vascular and Endovascular Surgery Society (VESS) Scientific Sessions (from 1:30 p.m. onward in the West Building, Level 1) will highlight areas of unmet need and offer paradigm-shifting…
Tackling inequities in venous care
During the 2024 American Venous Forum (AVF;March 3–6) in Tampa, Florida, multiple presenters discussed inequities in venous care with a focus on how to get more patients into research, how geographic and demographic factors determine care both pre- and post-COVID-19,…
Penumbra announces FDA clearance of Lightning Flash 2 for the treatment of PE
Penumbra has announced the US Food and Drug Administration (FDA) clearance and launch of Lightning Flash 2, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary embolism (PE), a press release states. Lightning Flash…